ReviewAmerican journal of respiratory and critical care medicine2024
Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events.
Open access · hybridAbstract readReview
In one paragraph
Review in American journal of respiratory and critical care medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
12.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 50 citations in OpenAlex.
- Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.The Lancet. Respiratory medicine · 2025Trial
- Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial.The Lancet. Respiratory medicine · 2025Trial
- Long-term effectiveness and safety of cystic fibrosis transmembrane conductance regulator modulators and their impact on the lives of people with cystic fibrosis.American journal of respiratory and critical care medicine · 2026Article
- Patient-Reported Health-Related Quality of Life in Romanian Patients with Cystic Fibrosis in the Era of Highly Effective CFTR Modulator Therapy: A National Cross-Sectional Mixed-Methods Survey.Journal of clinical medicine · 2026Article
- Mental Health in Cystic Fibrosis in the Modulator Era: Epidemiology, Prognostic Significance, and Therapeutic Implications.Journal of clinical medicine · 2026Review
- Inhalable gene and RNA therapy for cystic fibrosis: perspectives and progress in clinical development.Nanomedicine (London, England) · 2026Review
- Modulation of immune responses by elexacaftor/tezacaftor/ivacaftor therapy in cystic fibrosis: data from a compassionate use program.Respiratory research · 2026Article
- Advances in cystic fibrosis: CFTR modulator triple combinations.The European respiratory journal · 2026Article
- The clinical, psychosocial, and economic burden of cystic fibrosis lung disease in the era of CFTR modulator therapy.Annals of the American Thoracic Society · 2026Review
- Real-World Safety and Effectiveness of Elexacaftor, Tezacaftor, and Ivacaftor in People with Cystic Fibrosis and Advanced Lung Disease: A Two-Year Multicenter Cohort Study.International journal of molecular sciences · 2025Observational
- Elexacaftor/Tezacaftor/Ivacaftor in Children with Cystic Fibrosis: No Longer "If" but a Question of "When" to Start.American journal of respiratory and critical care medicine · 2025Article
- Article
- Cystic Fibrosis Year in Review 2024.Pediatric pulmonology · 2025Review
- VX-445 (elexacaftor) inhibits chloride secretion across human bronchial epithelial cells by directly blocking KCa3.1 channels.PNAS nexus · 2025Article
- Reported Adverse Events in Patients with CF Receiving Treatment with Elexacaftor/Tezacaftor/Ivacaftor: 5 Years Observational Study.Journal of clinical medicine · 2025Article
- Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis: A Review of Registry-Based Evidence.Journal of clinical medicine · 2025Review
- Unveiling the psychosocial impact of Elexacaftor/Tezacaftor/Ivacaftor therapy in Cystic Fibrosis patients.BMC pulmonary medicine · 2025Observational
- Depression and anxiety in adolescents with cystic fibrosis in Brazil: prevalence, stability over time, and relationship with treatment adherence.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2025Observational
- Real-world safety profile of elexacaftor/tezacaftor/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system.Frontiers in pharmacology · 2025Article
- Successful Therapy over 12 Months of People with Cystic Fibrosis with Rare Non-phe508del Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations with Elexacaftor/Tezacaftor/Ivacaftor (ETI).Advances in respiratory medicine · 2024Observational
Corrections and comments
- Commented on by
Authors and funding
12 authors at 8 institutions in 4 countries.
Bonnie RamseySeattle Children's Research Institute and Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington.
Christoph U CorrellThe Zucker School of Medicine at Hofstra/Northwell, New York, New York.
David R DeMasoBoston Children's Hospital, Boston, Massachusetts.
Edward McKoneSt. Vincent's Hospital, Dublin, Ireland.ORCID 0000-0002-5455-8208
Elizabeth TullisSt. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
Jennifer L Taylor-CousarNational Jewish Health, Denver, Colorado.
Chenghao ChuVertex Pharmaceuticals Incorporated, Boston, Massachusetts.
Nataliya VolkovaVertex Pharmaceuticals Incorporated, Boston, Massachusetts.
Neil AhluwaliaVertex Pharmaceuticals Incorporated, Boston, Massachusetts.
David WaltzVertex Pharmaceuticals Incorporated, Boston, Massachusetts.
Simon TianVertex Pharmaceuticals Incorporated, Boston, Massachusetts.
Marcus A MallDepartment of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin; and.ORCID 0000-0002-4057-2199
Vertex Pharmaceuticals (United States) · USBoston Children's Hospital · USHofstra University · USHumboldt-Universität zu Berlin · DENational Jewish Health · USSeattle Children's Hospital · USSt. Michael's Hospital · CASt. Vincent's University Hospital · IE
Funding
Translational Research Center to Expedite Novel Therapies in Cystic FibrosisP30DK089507 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · PI Christopher Hooper Goss, Lucas R Hoffman · 2010 to 2026
$21.4MNIDDK NIH HHS P30 DK089507
Abstract
PubMed holds no abstract for this paper.
Indexed as
AminophenolsBenzodioxolesCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorIndolesPyrazolesPyridinesPyrrolidinesQuinolonesDepressionHumansAminophenolsBenzodioxolesCystic Fibrosis Transmembrane Conductance RegulatorelexacaftorIndolesivacaftorPyrazolesPyridinesPyrrolidinesQuinolonestezacaftorCFTR modulatordepressionelexacaftor/tezacaftor/ivacaftormental health
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.